Mattehorn study showed EFS improvement and strong OS trend with FLOT+duravalumab. Great news to establish the global standard for fit patients with locally advanced gastric/GEJ cancer. Looking forward to the detail.@OncoAlert@oncodaily
https://t.co/2k7AXt6wIG
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY- Gastric04 Phase 3 Trial
👉ENHERTU more effective than Pacli/Ram
https://t.co/TOduG8XVv3
@myESMO
Very grateful that those oncologists who inspire me to #endcancer also happen to be incredible humans! Thanks to all for coming out in SF to celebrate life and love! ❤️🌈 #GI25
👏 Great to see this published!
VESTIGE is a negative randomised trial with an important lesson..
➡️ Give adjuvant FLOT even when there's residual cancer after neoadjuvant chemo.
👀 Looking forward to the translational work
https://t.co/4CvIhIzxwm
💵 Baselined: The Biden Economy
We are taking a snapshot of Joe Biden's economy before he leaves office so we have a point of comparison when Donald Trump begins to take credit for it, like he did the economy he inherited form Barack Obama.
Niche 2 after two doses of nivolumab and one dose of ipi and surgery. 100% of patients with MSI high colon cancer relapse free at 3 years. Arguably preop IO should be a new care standard in MSI high colon cancer.
Niche 2 after two doses of nivolumab and one dose of ipi and surgery. 100% of patients with MSI high colon cancer relapse free at 3 years. Arguably preop IO should be a new care standard in MSI high colon cancer.
Time to move away from radiotherapy in operable GEA #ESMO24
TOPGEAR ➡️ no survival benefit when RT added to periop chemo
TOPGEAR + ESOPEC : both great trials with a definitive answer = no more RT
✅Great drugs in development - let's focus on systemic Rx for cure @myESMO
Results of TOPGEAR trial indicate no survival benefit for adding radiation therapy to perioperative chemotherapy in gastroesophageal adeno carcinoma. Chemotherapy alone should be the standard of care with chemo radiotherapy only used in the nonoperative setting. ESMO 2024